体内
角膜新生血管
生物利用度
角膜
药理学
药代动力学
索拉非尼
新生血管
材料科学
生物医学工程
血管生成
化学
医学
眼科
癌症研究
生物
生物技术
肝细胞癌
作者
Qingqing Luo,Jingjing Yang,Haohang Xu,Jieran Shi,Zhen Liang,Rui Zhang,Ping Lü,Guojuan Pu,Ningmin Zhao,Junjie Zhang
出处
期刊:Drug Delivery
[Taylor & Francis]
日期:2022-03-11
卷期号:29 (1): 837-855
被引量:42
标识
DOI:10.1080/10717544.2022.2048134
摘要
Sorafenib (SRB), a multikinase inhibitor, is effective in reducing experimental corneal neovascularization (CNV) after oral administration; however, its therapeutic use in ocular surface disorders is restricted due to poor solubility and limited bioavailability. This study aimed to develop and optimize SRB-loaded nanostructured lipid carriers (SRB-NLCs) for topical ocular delivery by a central composite design response surface methodology (CCD-RSM). It was spherical and uniform in morphology with an average particle size of 111.87 ± 0.93 nm and a narrow size distribution. The in vitro drug release from the released SRB-NLC formulation was well fitted to Korsmeyer Peppas release kinetics. The cell counting kit-8 (CCK-8) cell viability assay demonstrated that SRB-NLC was not obviously cytotoxic to human corneal epithelial cells (HCECs). An in vivo ocular irritation test showed that SRB-NLC was well tolerated by rabbit eyes. Ocular pharmacokinetics revealed 6.79-fold and 1.24-fold increase in the area under concentration-time curves (AUC0-12h) over 12 h in rabbit cornea and conjunctiva, respectively, treated with one dose of SRB-NLC compared with those treated with SRB suspension. Moreover, SRB-NLC (0.05% SRB) and dexamethasone (0.025%) similarly suppressed corneal neovascularization in mice. In conclusion, the optimized SRB-NLC formulation demonstrated excellent physicochemical properties and good tolerance, sustained release, and enhanced ocular bioavailability. It is safe and potentially effective for the treatment of corneal neovascularization.
科研通智能强力驱动
Strongly Powered by AbleSci AI